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Objective: Soluble ST2 (sST2), a novel biomarker predictive for heart disease, has recently been shown
associated with the progression of atherosclerotic disease in a mouse model. The present study was
designed to assess sST2 plasma levels in patients scheduled for carotid endarterectomy and relate it with
the occurrence of adverse cardiovascular events during follow-up. In addition, sST2 levels were associ-
ated to patient clinical data and atherosclerotic plaque characteristics.
Methods and results: Plasma sST2 levels were measured in 391 patients who underwent carotid end-
arterectomy and were subsequently followed for 3 years. Primary composite endpoint was the occur-
rence of an adverse cardiovascular event.
At baseline, no differences were observed in sST2 levels between asymptomatic (n ¼ 75) and symp-
tomatic (n ¼ 316) patients (85 [49e122] versus 90 [58e137] pg/ml, p ¼ 0.263). Soluble ST2 plasma levels
did not differ between patients who experienced a secondary manifestation of cardiovascular disease
and patients who remained free of symptoms (90 [60e129] versus 88 [46e140] pg/ml, p ¼ 0.519).
There was no association between sST2 levels and any of the following plaque characteristics: size of a
lipid core, degree of calciﬁcation, number of macrophages or smooth muscle cells, amount of collagen
and number of microvessels.
Conclusions: Soluble ST2 plasma levels have no predictive value for future cardiovascular events in
patients with signiﬁcant carotid artery stenosis. In addition, we did not observe an association between
plasma sST2 levels and the histopathological features of a rupture prone plaque. This study does not
provide supportive evidence that sST2 reﬂects a progressive state of advanced atherosclerotic disease.
 2013 Elsevier Ireland Ltd. All rights reserved.1. Introduction
The aging population leads to an increase of cardiovascular
morbidity and mortality. Biomarkers may facilitate the identiﬁca-
tion of patients at high risk who subsequently can undergo pre-
ventive treatment. ST2, the receptor for the Th2 associated cytokinel Cardiology (Room G02.523),
100, 3584 CX Utrecht, The
2693.
llems).
nd Ltd. All rights reserved.interleukin (IL)-33, is a member of the IL-1 receptor family that has
recently gained signiﬁcant interest in the biomarker research ﬁeld.
As a result of alternative splicing, ST2 is expressed in a trans-
membrane form (ST2L) and a soluble form (sST2) [1]. Soluble ST2
has been studied extensively as it was shown to be elevated in
patients with cardiovascular disease [2,3]. Moreover, sST2 levels
were demonstrated to have predictive value for the occurrence of
future cardiovascular events in patients suffering from ischemic
heart disease [4].
ST2L, expressed on the surface of many inﬂammatory cells [5], is
the receptor trough which signalling of IL-33 has been found to
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models of cardiovascular disease resulted in functional improve-
ments and increased survival rates [6e8]. This might explain an
unfavourable role of sST2 in cardiovascular disease [6,8,9] since
capturing of IL-33 by the soluble form of ST2 from the circulation
hampers the beneﬁcial effect of IL-33 [10].
Previous human studies on the predictive value of sST2 for heart
failure and mortality mainly focussed on patients with ischemic
heart disease [11]. In the present study, we investigated the pre-
dictive value of sST2 on future cardiovascular atherosclerotic events
in a patient group with signiﬁcant carotid artery disease: in this
patient domain the predictive value of sST2 is still unknown. Sol-
uble ST2 protein levels were assessed in the plasma of patients that
underwent carotid endarterectomy and related to the occurrence of
adverse cardiovascular events during follow-up.
In patients with coronary and carotid artery disease, acute car-
diovascular manifestations are often the result of plaque rupture
followed by thrombus formation. Therefore, a particularly inter-
esting observation was that ApoE/ mice on a high fat-diet
receiving IL-33 treatment developed smaller lesions, while sST2
administration resulted in increased plaque size [9]. Experiments
showing that administration of IL-33 lowered foam cell formation
considerably in vitro and in vivo [12], further support an important
role for the IL-33/ST2 pathway in atherosclerotic plaque develop-
ment. Therefore, in the current study, associations between sST2
plasma levels and the characteristics of a vulnerable plaque have
been investigated.
2. Materials and methods
2.1. Study population and design
A total of 391 patients of the Athero-Express were included in
this study. The Athero-express biobank involves patients that
underwent carotid endarterectomy (CEA) in two Dutch teaching
hospitals in Utrecht and Nieuwegein the Netherlands [13]. Indica-
tion for CEA was based on recommendations by the Asymptomatic
Carotid Atherosclerosis Study, the North American Symptomatic
Carotid Endarterectomy Trial and the European Carotid Surgery
Trial [14e16]. Patients were operated between March 2002 and
August 2008 and randomly selected among those of whom blood
plasma samples were available. The local medical ethical boards of
both participating hospitals approved this study. The participating
patients signed a written informed consent prior to inclusion.
The patient’s baseline characteristics and medical history were
obtained via questionnaires and the patient medical records.
2.2. Follow-up
After CEA patients were followed up to 3 years by questionnaire.
Primary outcome was deﬁned as any cardiovascular event
including; (non-) fatal stroke, (non-) fatal myocardial infarction,
sudden death and other vascular death and any invasive arterial
intervention that had not been planned at the time of inclusion (e.g.
carotid surgery or angioplasty, coronary artery bypass grafting
(CABG), percutaneous transluminal coronary angioplasty (PTCA),
peripheral vascular surgery or angioplasty).
2.3. Materials
The carotid plaques used in this study were processed as
described previously [13]. In short, after surgical dissection the
plaque was cut into segments of 5 mm. The segment with the
largest plaque area was ﬁxed in formalin and embedded in parafﬁn
for histology. The two adjacent sections were frozen in liquidnitrogen and used for protein isolation. In addition, blood was
drawn prior to CEA procedure and plasma was stored at 80 C.
2.4. Quantiﬁcation of sST2 levels in patient plasma
Soluble ST2 levels were measured with an IL-1 R4/ST2 enzyme-
linked immunosorbent assay (ELISA, RayBiotech, Norcross, Georgia,
USA) according to the manufacturer’s instructions. In brief, plasma
samples 1:1 diluted with dilution buffer and standards were
incubated for 2.5 h in a 96-well plate pre-coated with a capture
antibody for human ST2. After the 96-well plate was washed using
an automatic washer, a biotin labelled anti-human ST2 antibody
was added to the wells. In between washes, the HRP antibody was
added, followed by administration of the substrate. After 30 min
the stop solutionwas added and the luminescencewasmeasured at
450 nm with an ELISA reader (Multiskan FC, Thermo Fisher Scien-
tiﬁc, Vantaa, Finland). The upper detection limit of the RayBio
human IL-1 R4/ST2 ELISA kit was 1200 pg/ml and the lower limit of
detection was 2 pg/ml, with an intra-assay CV<10% and inter-assay
CV<12%.
2.5. Plaque protein measurements
To investigate whether sST2 levels are associated with the pla-
que’s inﬂammatory status, we used expression data of pro-and
anti-inﬂammatory cytokines e.g. IL-2, IL-4, IL-5, IL-6, IL-8, IL-10,
INF-g and TNF-a that were available from measurements of a
previous study. These expression levels had been assessed in 211 of
the carotid atherosclerotic plaques that were included for the cur-
rent study by Fluorescent Bead Immunoassay 810FF (Bendermed
Systems, Vienna, Austria).
2.6. Kidney function assessment
Kidney function was determined by calculating the glomerular
ﬁltration rate (eGFR) expressed in ml/min/1.73 m2 as previously
described [17]. Serum creatinin was measured in blood plasma.
2.7. Immunohistochemistry
Consecutive sections were stained for CD68 (macrophages),
smooth muscle cells (alpha actin) CD66 (neutrophils), mast cell
tryptase (mast cells) and CD34 (endothelial cells). As previously
described, image-analyzing software (Soft Imaging Solutions
GmbH, Münster, Germany) was used to determine positive
macrophage and smooth muscle cell staining expressed as a per-
centage of covered plaque area. Microvessels were counted in three
hot-spots and were expressed as average microvessel density per
hotspot [18]. The presence of intraplaque hemorrhagewas assessed
with Hematoxylin and Eosin (H&E) staining and ﬁbrin (Mallory’s
phosphotungstic acid-hematoxylin) [19]. Calciﬁcation (H&E) and
collagen content (Picrosirius red) were scored semi-quantitatively.
The size of the extracellular lipid core (atheroma) was assessed by
the H&E and Picrosirius red stain [13]. Overall plaque phenotype
was based on the percentage of conﬂuent lipid areas of the total
plaque area that were visually estimated (ﬁbrous: <10% fat;
ﬁbroatheromatous: 10%e40%; atheromatous: >40% fat).
2.8. Statistics and data analysis
IBM SPSS statistics version 20 was used for all analyses (IBM
corporation, Armonk, NY, USA). Soluble ST2 levels are not normally
distributed; non-parametrical testing was used to determine dif-
ferences. The Wilcoxon signed rank test was applied to compare
differences in sST2 levels before and after surgery. The Spearman
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between sST2 and all continuous variables in this study.
The ManneWhitney U test was used to study sST2 levels as a
continuous variable for all risk factors. To assess the independent
association between sST2 plasma levels and history of cardiovas-
cular events and interventions, a binary logistic regression model
was used in which we corrected for the potential confounders age
and diabetes. The relation between sST2 and the occurrence of
future manifestations during follow-up was examined using the
cox-regression survival analysis. Differences were considered
signiﬁcant with a p-value of below 0.05.
3. Results
3.1. Baseline characteristics
Soluble ST2 plasma levels were measured in a total of 391 pa-
tients that underwent carotid endarterectomy. In Table 1 the
baseline clinical characteristics of the patients are depicted. With a
mean age of 67 years and 67%males, the study population reﬂects a
relatively typical population of patients with cerebral vascular
occlusive diseases. Themajority of patients was symptomatic (81%),
hypertensive (87%) and used statins (74%).
3.2. Soluble ST2 plasma levels and clinically relevant characteristics
Table 1 summarises the associations between sST2 expression
levels and relevant clinical characteristics. Plasma sST2 levels
correlated with age (r ¼ 0.240, p ¼ 0.037). Higher sST2 levels were
observed in males compared to females (91.8 [62.3e145.0] versus
76.7 [47.1e111.2] pg/ml, p ¼ 0.002) and in patients with diabetesTable 1
Baseline characteristics of the patients in relation to sST2 plasma levels.
sST2 (pg/mL) p-value
Age, mean years (sd) 67 (9) r ¼ 0.119 0.018
BMI, mean kg/m2 (sd) 27 (4) r ¼ 0.053 0.318
Sex
Male 263/391 (67%) 91.8 [62.3e145.0] 0.002
Female 128/391 (33%) 76.7 [47.1e111.2]
Current smoker
Yes 133/383 (35%) 90.5 [53.8e137.8] 0.926
No 250/383 (65%) 89.4 [60.4e128.2]
Diabetes mellitus
Yes 88/391 (23%) 106.4 [62.8e181.6] 0.021
No 303/391 (77%) 88.0 [55.0e125.3]
Statin use
Yes 288/389 (74%) 89.5 [55.6e141.8] 0.591
No 101/389 (26%) 88.3 [58.0e124.4]
Hypertension
Yes 340/391 (87%) 88.5 [57.5e130.5] 0.588
No 51/391 (13%) 100.9 [57.2e127.4]
History peripheral intervention
Yes 71/391 (18%) 95.3 [64.9e160.4] 0.244
No 320/391 (82%) 88.7 [56.1e126.9]
History coronary artery disease
Yes 104/391 (27%) 100.8 [69.6e153.4] 0.007
No 285/391 (73%) 84.4 [52.6e126.4]
Clinical presentation
Asymptomatic 75/391 (19%) 85.1 [48.6e121.5] 0.263*
Symptomatic 316/391 (81%) 90.0 [58.2e136.8]
Amaurosis fugax 56/316 (18%) 89.0 [59.4e164.1]
TIA 180/316 (57%) 91.8 [55.3e127.1]
Stroke 80/316 (25%) 87.7 [63.4e155.4]
Data are presented as No. (%) and median [IQR] unless otherwise indicated;
r ¼ Spearman’s rank correlation coefﬁcient; sd ¼ standard deviation;
IQR¼ interquartile range; BMI¼ bodymass index; TIA¼ transient ischemic attack; *
p-value represents statistical analysis for asymptomatic patients versus symptom-
atic patients (composed of amaurosis fugax, TIA and stroke).mellitus (106.4 [62.8e181.6] versus 88.0 [55.0e125.3] pg/ml,
p ¼ 0.021). Furthermore, we observed that patients with a history
of coronary artery disease that previously experienced amyocardial
infarction (MI) or underwent PTCA/CABG had higher sST2 levels
(100.8 [69.6e153.4] versus 84.4 [52.6e126.4] pg/ml; p ¼ 0.007).
However, in a logistic regression model controlling for age and
diabetes, sST2 levels were no longer associated with previous MI or
coronary interventions. Soluble ST2 levels were not signiﬁcantly
higher in patients that previously underwent a peripheral artery
intervention (95.3 [64.9e160.4] versus 88.7 [56.1e126.9] pg/ml;
p ¼ 0.244).
Clinical presentation was not associated with sST2 levels: no
differences were observed in sST2 levels between asymptomatic
patients (n ¼ 75) and symptomatic (n ¼ 316) patients (85 [49e122]
versus 90 [58e137] pg/ml, p ¼ 0.263). Additionally, no association
was found between sST2 levels and the delay between surgery and
presentation of symptoms.
3.3. Relation of sST2 and other biomarkers
A correlation was found between sST2 and the acute phase
protein CRP mg/l (r ¼ 0.107, p ¼ 0.035). Kidney function expressed
as eGFR (ml/min/1.73 m2) correlated negatively with sST2
(r ¼ 0.165, p ¼ 0.008).
3.4. Outcome
A total of 75 out of 391 patients suffered from secondary car-
diovascular manifestations during a 3-year follow-up. There was no
signiﬁcant difference in baseline sST2 plasma levels between
patients that did and those that did not experience a cardiovascular
event (90 [60e129] versus 88 [46e140] pg/ml, p¼ 0.519). Likewise,
when divided into two groups by the median, high sST2 levels did
not associate with secondary manifestations of cardiovascular
disease (39 [20%] in the low level sST2 group versus 36 [19%] events
in the high sST2 group; Fig. 1). Median sST2 levels were higher in
patients that experienced a cardiac event (n ¼ 10), but this did not
reach signiﬁcance (p ¼ 0.324). Soluble ST2 plasma levels were
signiﬁcantly higher in patients with all-causemortality (88.2 versus
111.8 pg/ml; n ¼ 24, p ¼ 0.031). However in a cox regressionFig. 1. KaplaneMeier survival curves for sST2 plasma levels versus combined cardio-
vascular outcome after carotid endarterectomy. High sST2 levels (continuous line)
versus low sST2 levels (dashed line) based on the median (89 pg/ml) as a cut-off value
(p ¼ 0.861). The numbers of patients at risk for cardiovascular events are shown at 0, 1,
2 and 3 years after endarterectomy.
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dictive (p ¼ 0.134)
3.5. Plasma sST2 levels and plaque characteristics
As depicted in Table 2, sST2 levels were not associated with
plaque phenotype categorised in three groups: ﬁbrous, ﬁbroa-
theromatous, atheromatous (88.2 [48.9e126], 85.5 [53.3e130.9],
92 [67.1e139.8] pg/ml respectively; p ¼ 0.242). There was no as-
sociation between sST2 levels and any of the following plaque
characteristics: calciﬁcation, collagen, smooth muscle cells, mac-
rophages, neutrophils or mast cells (Tables 2 and 3). In addition,
sST2 levels were not related to the plaque protein levels of the anti-
or pro- inﬂammatory cytokines (Table 3). Although no association
was found between sST2 levels and microvessel density, an in-
crease of sST2 level was observed in patients with plaques that
scored positive for intraplaque hemorrhage (92.6 [61.9e144.9]
versus 80.3 [49.4e107.5] pg/ml, p ¼ 0.004).
4. Discussion
Soluble ST2 is emerging as a novel biomarker for prediction of
mortality and heart failure in patients with established cardiac
disease. Multiple studies showed that sST2 is a biomarker that adds
value in risk prediction for development of cardiac disease on top of
traditional risk factors and other biomarkers in patients with
ischemic heart disease [11]. Stenosis or rupture of the atheroscle-
rotic plaque is the underlying cause for myocardial infarction or
heart failure of ischemic aetiology. Experimental studies have
shown a possible role for the IL-33/ST2 pathway in progression of
the atherosclerotic plaque [9,12], but studies revealing an associa-
tion between sST2 and atherosclerotic lesion phenotype in humans
is lacking. Therefore, we aimed to investigate whether sST2 levels
would have predictive value for adverse cardiovascular events in a
patient group with clinically manifest cerebral artery disease. In
addition, the dissection of atherosclerotic plaques in this patient
group allowed an association study between sST2 levels and
atherosclerotic plaque phenotype.
Here we show that baseline sST2 levels have no predictive value
for future combined cardiovascular events in a patient group with
severe carotid stenosis that underwent an endarterectomy. Our
results suggest that sST2 is a less potent biomarker for adverse
events in the presence of cerebral ischemic disease compared to
patients suffering from cardiac ischemic disease. There are several
potential explanations for this observation. In the presence of
myocardial infarction and subsequent heart failure, severe tissueTable 2
Soluble ST2 plasma levels with respect to the histological parameters of the plaque.
sST2 (pg/mL) p-value
Plaque phenotype
Fibrous 125/391 (32%) 88.2 [48.9e126.0] 0.242
Fibroatheromatous 143/391 (37%) 85.5 [53.3e130.9]
Atheromatous 123/391 (31%) 92.2 [67.1e139.8]
Intraplaque haemorrhage
Yes 272/391 (70%) 92.6 [61.9e144.9] 0.004
No 119/391 (30%) 80.3 [49.4e107.5]
Collagen
Minor 76/391 (19%) 106.0 [60.4e142.7] 0.402
Moderate 219/391 (56%) 86.5 [56.2e127.3]
Heavy 96/391 (25%) 88.1 [57.4e132.4]
Calciﬁcation
No/minor 168/391 (43%) 86.9 [56.6e143.0] 0.619
Moderate/heavy 223/391 (57%) 89.8 [57.4e127.1]
Data are presented as Spearman’s rank correlation coefﬁcient (r) or median [inter-
quartile ranges].damage and remodelling takes place in a relatively short time span
whereas in the presence of carotid stenosis tissue damage may be
minimal or temporary. Furthermore, a signiﬁcant number of
patients suffered from relative minor complications as transient
ischemic attack or amaurosis fugax. Another explanation is that
bloodwas drawnprior to surgerywhich is executedweeks after the
index event whereas in cardiac ischemia the intervention is
executed mostly in the acute phase.
No difference in sST2 levels was observed between asymp-
tomatic and symptomatic patients at the moment of admission for
surgery. Previous studies have shown that sST2 rises to extreme
levels within 24 h after myocardial infarction or cardiovascular
interventions after which they return to baseline levels within a
few days [20e22]. This indicates that the time of blood withdrawal
is of great importance since the delay following a cardiovascular
event strongly inﬂuences sST2 levels. Therefore, we examined
whether the delay between operation and the presentation of
symptoms was associated with sST2 levels. We showed that the
delay did not alter the sST2 levels. However, it merits careful
consideration that patients were often scheduled about 10 weeks
after presenting clinical symptoms, which might explain the nor-
malisation of sST2 levels. Current guidelines have resulted in much
shorter delays between the cerebrovascular event and surgery
which is relevant before extrapolating results to current practice. In
the current follow-up study we could not select sufﬁcient numbers
of patients presenting with stroke who were operated within 1e2
weeks to investigate whether sST2 levels were increased within
this few day time frame.
Interestingly, higher sST2 levels were observed in patients with
previous cardiac events or coronary interventions, but not in
patients with history of peripheral interventions. However, after
adjusting for confounders in a logistic regression model, other risk
factors were found to be responsible for this effect. Unfortunately,
we were underpowered for analysing risk prediction in the sub-
group of patients suffering from adverse cardiac events during
follow-up. Nevertheless, in line with previous research, a positive
correlation between all-cause mortality and sST2 levels was
observed [23e28]. We conﬁrmed the previously reported positive
association between CRP and sST2 levels [3,24,28e30]. Further-
more, our data concord with previous studies associating sST2
levels with, age, gender and diabetes mellitus [23,26,30e33]. In
addition, in our cohort a positive correlation between sST2 and CKD
was observed conﬁrming previous observations [34]. This is of
interest as CKD has previously been shown one of the most
important determinants for future cardiovascular events [17].
Another research question we addressed was whether sST2
levels associated with plaque phenotype. Previously, sST2 admin-
istration in ApoE/ mice resulted in the development of larger
atherosclerotic plaques, although collagen content and inﬂamma-
tory and smooth muscle cell numbers were not altered [9].
We studied advanced atherosclerotic disease and therefore our
study cannot address the question if sST2 plasma levels are asso-
ciated with plaque size in humans. However, we could investigate
whether sST2 levels were associated with histological markers of
plaque vulnerability. In line with the previously reported mouse
data, we showed that sST2 plasma levels in patients with carotid
artery disease are not related to most of the established charac-
teristics of the rupture-prone atherosclerotic plaques. Nevertheless,
we observed an association with intraplaque bleeding which war-
rants further research since plaque hemorrhage is considered an
emerging determinant of plaque destabilisation.
Signalling of IL-33 trough ST2L has been found to stimulate Th2
associated cytokine production [35], which is abolished by sST2
acting as a decoy receptor for IL-33 [10]. We therefore investigated
whether high levels of sST2 would prevent Th2 associated cytokine
Table 3
Soluble ST2 plasma levels with respect to inﬂammatory markers in the plaque.
Q1 Q2 Q3 Q4 p-value Spearman (r) p-value
sST2 pg/ml [<57.4] [57.4e89.4] [98.5e130.3] [>130.3]
Plaque histology
Patient numbers (n) 98 99 97 97
Microvessel density 8.3 [5.7e11.3] 8.3 [5.2e11.7] 7.7 [5.0e11.1] 7.7 [4.8e11.9] 0.489 0.028 0.624
Smooth muscle cells 2.01 [0.74e3.83] 2.65 [0.96e4.12] 1.55 [0.52e3.14] 1.69 [0.55e4.02] 0.088 0.085 0.094
Macrophages 0.72 [0.18e1.50] 0.75 [0.22e2.08] 0.68 [0.17e1.35] 0.65 [0.18e1.54] 0.376 0.035 0.491
Plaque protein
Patient numbers (n) 49 62 51 49
IL-2 pg/ml 184 [0e357] 229 [104e533] 153 [4e335] 190 [0e364] 0.104 0.004 0.950
IL-4 pg/ml 144 [0e351] 180 [70e372] 126 [0e283] 168 [0e316] 0.329 0.016 0.819
IL-5 pg/ml 126 [22e324] 153 [65e358] 116 [56e231] 123 [0e304] 0.609 0.037 0.594
IL-6 pg/ml 53 [16e125] 50 [12e139] 38 [18e81] 31 [14e75] 0.667 0.098 0.158
IL-8 pg/ml 41 [8e164] 48 [7e230] 60 [6e153] 43 [1e151] 0.888 0.047 0.497
IL-10 pg/ml 18 [0e64] 22 [8e78] 14 [0e40] 20 [0e51] 0.280 0.011 0.868
TNF-a pg/ml 12 [0e28] 12 [4e39] 8 [0e22] 15 [0e33] 0.621 0.030 0.662
IFN-y pg/ml 53 [3e248] 90 [29e318] 78 [14e177] 91 [8e235] 0.473 0.023 0.740
Data are presented as Spearman’s rank correlation coefﬁcient (r) or median [interquartile ranges].
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kines. In this study we did not ﬁnd an association between sST2
levels and any of the cytokines related to a Th1 or Th2 inﬂammatory
response in the plaque. Taken together, these data suggest that
serum sST2 levels do not inﬂuence atherosclerotic plaque pro-
gression nor their inﬂammatory proﬁle. Keeping in mind that sST2
levels increase fast and to extreme levels after trauma or surgical
procedures, this might indicate that sST2 is just a plain marker for
systemic inﬂammation.
5. Conclusions
The associations found between sST2 and traditional risk fac-
tors, other biomarkers and all-cause mortality are in line with
previous studies. Soluble ST2 levels have not been found associated
with any of the histopathological characteristics of a rupture-prone
plaque. Together with the observation that sST2 levels are not
elevated in patients that develop secondary cardiovascular events,
this study suggests that sST2 levels are not related to progression of
atherosclerotic disease following cerebrovascular ischemia. This
implies that sST2 levels may have added value in risk prediction for
cardiac disease in patients with acute manifestations of myocardial
ischemia or severe chronic heart failure, but not in a subgroup of
patients with cerebrovascular disease.
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